That's true, FDA did help the little guy by giving trial OKs without a lot of preliminary BS. The fact is Gilead is a much larger company, by far, and was able to quickly initiate and fill out their trials. CytoDyn is limping along as best they can. The name 'leronlimab' will start rolling off the tongues of the major network talking heads soon enough. Patience.